Fadlo Khuri, M.D.

Fadlo  Khuri, M.D.
Emory Clinic

Professor of Hematology and Oncology

Associate Director, Clinical and Translational Research

Chief Medical Officer and Director of the Aerodigestive Tract Cancer Program

Frnaces Blomeyer Chair in Translational Lung Cancer Research, Deputy Director WCI

Emory Healthcare Network Physician
Medical Oncology (Board certified since 1997)
Internal Medicine (Board certified since 1992)
Areas of Clinical Interest:
esophageal cancer
head & neck cancer
lung cancer
thyroid cancer
Office(s) Locations:
Emory Clinic 'C'
1365 Clifton Rd NE ste 1500
Atlanta, GA 30322
(404) 778-1900
Hospital Affiliation(s):
Emory University Hospital
About Dr. Khuri

Dr. Khuri has been considered one of the leading translational clinical investigators and physicians in lung and aerodigestive medical oncology in the world for the last decade.

Dr. Khuri’s major contributions have been innovations in the areas of: Novel approaches to the therapy and prevention of lung and upper aerodigestive tract cancer; Developing careful mechanism-based combinations of oncolytic viruses and/or small molecules with cytotoxic chemotherapy; and exploring the mechanism of action of these agents in the setting of prevention and therapy in collaboration with basic scientists and clinical investigators, interrogating the retinoid receptors and cyclo-oxygenase-2 as prognostic markers in non-small cell lung cancer (NSCLC).

Dr. Khuri is Principal Investigator on the lung cancer program project grant entitled “Targeting cell signaling in lung cancer to enhance therapeutic efficacy” (1 P01 CA116676-01A1) for a total of $7.9 million. In that capacity, he has overall responsibility for the direction and progress of this grant with the final authority for decision making.

This translational research endeavor is comprised of four basic science research projects and three cores, and also includes three clinical trials. He serves as co-leader on Project 1 entitled “Modulation of the mTOR pathway for lung cancer treatment” and Director of the Administration Core, which oversees the entire program. Matching funds of $2.5 million have been promised from the Georgia Cancer Coalition over five years of this program. The Winship Cancer Institute of Emory University and the Emory School of Medicine have pledged $500,000 and $750,000, respectively, over the duration of this program.

He is the co-leader of the Head and Neck Cancer SPORE (Specialized Program of Research Excellence) (HNC SPORE) with Dr. Dong Moon Shin for a total of $12.5 million. The first year of this grant was highlighted by the effective integration of all research projects with the clearly defined goals, core functions, developmental research and career development programs from our initial proposal. The overall goal of the Emory Winship SPORE is to improve prevention and treatment of Head and Neck Cancer, with an emphasis on new discoveries and their rapid translation to patients who are suffering disability and morbidity caused by this disease.

Emory’s Head and Neck Cancer SPORE program consists of four major translational research projects, two research cores, an administrative core, and two research programs involving career development and developing research programs. The Head and Neck Cancer SPORE is indeed a truly interdisciplinary approach to meeting goals and objectives by carrying out projects with co-investigators in basic, translational and clinical science. Substantial progress has been made in the first year.

Medical School
Columbia University, New York, NY

Boston University School of Medicine, Boston, MA

Boston University School of Medicine, Boston, MA

Tufts University School of Medicine, Boston, MA